GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (LTS:0GTN) » Definitions » Price-to-Owner-Earnings

BioGaia AB (LTS:0GTN) Price-to-Owner-Earnings : 32.17 (As of Apr. 30, 2024)


View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB Price-to-Owner-Earnings?

As of today (2024-04-30), BioGaia AB's share price is kr115.50. BioGaia AB's Owner Earnings per Share (TTM) ended in Dec. 2023 was kr3.59. It's Price-to-Owner-Earnings for today is 32.17.


The historical rank and industry rank for BioGaia AB's Price-to-Owner-Earnings or its related term are showing as below:

LTS:0GTN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.16   Med: 34.79   Max: 82.6
Current: 32.21

During the past 13 years, the highest Price-to-Owner-Earnings of BioGaia AB was 82.60. The lowest was 20.16. And the median was 34.79.


LTS:0GTN's Price-to-Owner-Earnings is ranked worse than
57.24% of 421 companies
in the Drug Manufacturers industry
Industry Median: 28.39 vs LTS:0GTN: 32.21

As of today (2024-04-30), BioGaia AB's share price is kr115.50. BioGaia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr3.63. Therefore, BioGaia AB's PE Ratio for today is 31.82.

As of today (2024-04-30), BioGaia AB's share price is kr115.50. BioGaia AB's EPS without NRI for the trailing twelve months (TTM) ended in was kr3.63. Therefore, BioGaia AB's PE Ratio without NRI for today is 31.82.

During the past 13 years, BioGaia AB's highest PE Ratio without NRI was 68.58. The lowest was 17.46. And the median was 35.84.


BioGaia AB Price-to-Owner-Earnings Historical Data

The historical data trend for BioGaia AB's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB Price-to-Owner-Earnings Chart

BioGaia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.53 43.80 50.79 22.33 27.97

BioGaia AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.33 24.21 30.06 24.13 27.97

Competitive Comparison of BioGaia AB's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Price-to-Owner-Earnings falls into.



BioGaia AB Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

BioGaia AB's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=115.50/3.59
=32.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioGaia AB  (LTS:0GTN) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


BioGaia AB Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of BioGaia AB's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


BioGaia AB (LTS:0GTN) Business Description

Traded in Other Exchanges
Address
Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.

BioGaia AB (LTS:0GTN) Headlines

No Headlines